image
Healthcare - Medical - Instruments & Supplies - NASDAQ - JE
$ 16.61
0.728 %
$ 1.83 B
Market Cap
-10.65
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVCR stock under the worst case scenario is HIDDEN Compared to the current market price of 16.6 USD, NovoCure Limited is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVCR stock under the base case scenario is HIDDEN Compared to the current market price of 16.6 USD, NovoCure Limited is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVCR stock under the best case scenario is HIDDEN Compared to the current market price of 16.6 USD, NovoCure Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVCR

image
$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
605 M REVENUE
18.82%
-170 M OPERATING INCOME
26.78%
-169 M NET INCOME
18.55%
-26.4 M OPERATING CASH FLOW
64.04%
-140 M INVESTING CASH FLOW
-76.16%
90.3 M FINANCING CASH FLOW
472.08%
161 M REVENUE
3.98%
-63.3 M OPERATING INCOME
-97.26%
-65.9 M NET INCOME
-115.64%
-3.45 M OPERATING CASH FLOW
-33.26%
-22.2 M INVESTING CASH FLOW
-217.90%
2.68 M FINANCING CASH FLOW
2585.00%
Balance Sheet NovoCure Limited
image
Current Assets 1.11 B
Cash & Short-Term Investments 960 M
Receivables 102 M
Other Current Assets 44.6 M
Non-Current Assets 134 M
Long-Term Investments 0
PP&E 120 M
Other Non-Current Assets 14.6 M
77.36 %8.23 %3.60 %9.64 %Total Assets$1.2b
Current Liabilities 756 M
Accounts Payable 105 M
Short-Term Debt 101 M
Other Current Liabilities 550 M
Non-Current Liabilities 124 M
Long-Term Debt 0
Other Non-Current Liabilities 124 M
11.93 %11.48 %62.48 %14.11 %Total Liabilities$880.6m
EFFICIENCY
Earnings Waterfall NovoCure Limited
image
Revenue 605 M
Cost Of Revenue 137 M
Gross Profit 468 M
Operating Expenses 639 M
Operating Income -170 M
Other Expenses -1.87 M
Net Income -169 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)605m(137m)468m(639m)(170m)2m(169m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
77.33% GROSS MARGIN
77.33%
-28.17% OPERATING MARGIN
-28.17%
-27.86% NET MARGIN
-27.86%
-46.82% ROE
-46.82%
-13.59% ROA
-13.59%
-37.44% ROIC
-37.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NovoCure Limited
image
100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -169 M
Depreciation & Amortization -14.4 M
Capital Expenditures -42.9 M
Stock-Based Compensation 160 M
Change in Working Capital 0
Others -3.37 M
Free Cash Flow -69.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NovoCure Limited
image
Wall Street analysts predict an average 1-year price target for NVCR of $24.1 , with forecasts ranging from a low of $14.5 to a high of $30 .
NVCR Lowest Price Target Wall Street Target
14.5 USD -12.70%
NVCR Average Price Target Wall Street Target
24.1 USD 45.09%
NVCR Highest Price Target Wall Street Target
30 USD 80.61%
Price
Max Price Target
Min Price Target
Average Price Target
353530302525202015151010May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership NovoCure Limited
image
Sold
0-3 MONTHS
831 K USD 6
3-6 MONTHS
83.5 K USD 3
6-9 MONTHS
13.9 K USD 1
9-12 MONTHS
69.1 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! fool.com - 1 month ago
NovoCure Q4 2024 Earnings: Strong And Growing Pipeline NovoCure remains a strong buy due to robust earnings, a growing core business, and a promising pipeline, particularly in lung and pancreatic cancer treatments. Q4 2024 earnings showed strong revenue growth despite an EPS miss driven by a stock-comp event related to FDA approval. Updated DCF analysis yields a $34 price target, with Wall Street consensus at $35.83, indicating significant upside potential. seekingalpha.com - 1 month ago
NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs will rise in 2025. seekingalpha.com - 1 month ago
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.45 per share a year ago. zacks.com - 1 month ago
NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript NovoCure Limited (NASDAQ:NVCR ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Chairman Ashley Cordova - Chief Executive Officer Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive Vice President & President, NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Lei Huang - Wells Fargo Vijay Kumar - Evercore ISI Tanmay Patwardhan - JPMorgan Emily Bodnar - H.C. Wainwright Operator Good day, and thank you for standing by. seekingalpha.com - 1 month ago
NovoCure Q4 EPS Misses, Revenue Matches Oncology treatment pioneer NovoCure (NVCR) reported mixed fourth-quarter 2024 earnings on Thursday, Feb. 27. Q4 revenue matched analysts' consensus expectations at $161.3 million and jumped 21% year over year. fool.com - 1 month ago
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland BAAR, Switzerland--(BUSINESS WIRE)--Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland. businesswire.com - 2 months ago
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update. businesswire.com - 3 months ago
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference. businesswire.com - 3 months ago
Why NovoCure Stock Was Winning Big This Week Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts. fool.com - 4 months ago
8. Profile Summary

NovoCure Limited NVCR

image
COUNTRY JE
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.83 B
Dividend Yield 0.00%
Description NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Contact No. 4 The Forum, Saint Helier, JE2 4UF https://www.novocure.com
IPO Date Oct. 1, 2015
Employees 1488
Officers Mr. Mukund Paravasthu Chief Operating Officer Ms. Ingrid Goldberg Vice President of Investor Relations Mr. Michael Puri Chief Human Resources Officer Dr. Uri Weinberg M.D., Ph.D. Chief Innovation Officer Mr. Christoph Brackmann Chief Financial Officer Mr. Barak Ben-Arye General Counsel Mr. Frank Leonard Executive Vice President & President of Novocure Oncology Dr. Nicolas Leupin M.B.A., M.D., Ph.D. Chief Medical Officer Ms. Ashley Cordova Chief Executive Officer Mr. William F. Doyle Executive Chairman